Neuromyelitis Optica Spectrum Disorder

DrugDrug NameDrug Description
DB01257EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
DB12530InebilizumabA humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
DrugDrug NamePhaseStatusCount
DB00112Bevacizumab1Completed1
DB11850Ublituximab1Completed1
DB00188Bortezomib2Completed1
DB00028Human immunoglobulin G2Completed1
DB00993Azathioprine2 / 3Completed1
DB01257Eculizumab2 / 3Recruiting1
DB00073Rituximab2 / 3Completed1
DB01257Eculizumab3Active Not Recruiting1
DB01257Eculizumab3Terminated1
DB11580Ravulizumab3Recruiting1
DB00073Rituximab4Active Not Recruiting1